



ALLIA.161APC1

PATENT

I FW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Keipert et al.  
Serial No. : 10/760,572  
Filed : January 20, 2004  
For : Amelioration Of Ischemic Damage  
Using Synthetic Oxygen Carriers  
Examiner : Not Assigned  
Group Art Unit : 3763

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent Office; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 13, 2005:

1/13/05  
  
John E. Wurst

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references for the above listed patent application. Copies of the references can be found in parent application 09/530,075. This Supplemental Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97 (b) (3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17 (p) to Deposit Account 01-1008. A duplicate copy of this Statement is enclosed for that purpose.

If there are any questions concerning this Information Disclosure Statement please call the undersigned at the number listed below.

Respectfully submitted,  
ALLIANCE PHARMACEUTICAL CORP.

Dated: 1/12/05

By:

John Wurst  
Registration No. 40,283  
(858) 410-5174

01/21/2005 CNGUYEN 00000044 011008 10760572

01 FC:1806 180.00 DA

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE	ATTY DOCKET NO. ALLIA.161APC1	APPLICATION NO. 10/760,572
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Keipert, et al.	
	FILING DATE 1/20/04	GROUP 3763

										U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	D N	O U	C M	U B	M E	E R	N	T	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5	0	8	5	6	3	0		2/1992	Osterholm et al.			
	5	7	2	3	4	9	6		3/1998	Nakada, Tsutomu			
	6	0	4	4	8	4	5		4/2000	Lewis, Brian Douglas			

										FOREIGN PATENT DOCUMENTS			
EXAMINER INITIAL	D N	O U	C M	U B	M E	E R	N	T	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	9	2	1	0	2	2	1		6/1992	PCT			
	0	0	3	7	9	9	2		10/1981	European			
	0	0	8	8	9	5	4		09/1983	European			
	9	6	4	0	0	9	7		12/1996	PCT			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Symons et al., "Perflubron Emulsion Increases Tolerance to myocardial ischemia in the isolated rabbit heart."; Document XP-002104379; Cardiovascular Research, Alliance Pharmaceutical Corp., 1995, FASEB Journal, Vol. 9, No. 3; pp. A622
	Hale et al., "Effect of Perfluorocarbon Emulsions on reperfusion injury after coronary artery occlusions in rabbits"; Basic Res. Cardiol 90:404-409; 1995
	Mosca R S et al., "Perfluorocarbon supplementation and postischemic cardiac function"; Surgery; 120(2), pgs. 197-204 (Aug. 1996).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	